MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
复制标题
DOI：
10.1111/bjh.12763
复制
发表时间：
2014-05-01
影响因子：
6.5
通讯作者：
Weisenburger, Dennis D.
中科院分区：
文献类型：
--
作者：
Perry, Anamarija M.;Alvarado-Bernal, Yuridia;Weisenburger, Dennis D.
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性疾病，“双重打击”DLBCL，同时存在MYC和BCL2易位，预后较差。在这项研究中，我们研究了组织中 MYC 和 BCL2 蛋白的表达是否可以预测 DLBCL 的生存。该研究包括 106 例新发 DLBCL 病例，使用利妥昔单抗和环磷酰胺、阿霉素、长春新碱和泼尼松 (R-CHOP) 或类 CHOP 方案治疗。结果在 205 名 DLBCL 患者的独立队列中得到验证。 BCL2 低表达 (50%) 的患者预后最差。在多变量分析中，BCL2 和 MYC 的组合是总生存期 (OS) 和无事件生存期 (EFS) 的独立预测因子（分别为 P=0 中心点 015 和 P=0 中心点 005）。 BCL2 和 MYC 高表达患者的死亡风险是低表达患者的九倍。高 BCL2 和 MYC 是 OS 较差的有力预测因子 (P
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and "double-hit" DLBCL, with both MYC and BCL2 translocations has a poor prognosis. In this study, we investigated whether MYC and BCL2 protein expression in tissue would predict survival in DLBCL. The study included 106 cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or CHOP-like regimens. The results were validated on an independent cohort of 205 DLBCL patients. Patients with low expression of BCL2 (50%) had the worst outcome. In multivariate analysis, the combination of the BCL2 and MYC was an independent predictor of overall survival (OS) and event-free survival (EFS) (P=0 center dot 015 and P=0 center dot 005, respectively). The risk of death was nine times greater for patients with high BCL2 and MYC compared to those with low expression. High BCL2 and MYC was a strong predictor of poor OS (P